CA-SMARTFRAME
13.2.2024 15:15:33 CET | Business Wire | Press release
Truepic, provider of secure content transparency infrastructure, and SmartFrame Technologies, a leading UK-based tech provider that is redefining the digital image standard, have deployed the first secure image protection model that is set to redefine the landscape of authenticity and uncompromised security with provenance in the global sports photography space.
SmartFrame, with its innovative image-streaming technology, has made substantial strides in ensuring the integrity and ownership of media collections. Photos backed by Truepic's trusted certificate authority undergo a seamless and secure verification process that compliantly signs SmartFrame's visual media at scale. Every image is equipped with the Coalition for Content Provenance and Authenticity’s (C2PA) Content Credentials, marking sports brands’ assets as authentic and providing a trusted source of information for online viewers.
Recognizing the importance of ensuring transparency and authenticity online, multiple sports enterprises and brands, such as Six Nations Rugby, New Zealand Rugby, and Manchester City F.C. have embraced SmartFrame’s image-streaming distribution model, supported by Truepic’s certificate authority. These premier sports organizations are elevating global brand protection while simultaneously contributing to a safer and more reliable online image ecosystem within sports photography. Furthermore, by adopting secure image streaming and embedding C2PA Content Credentials, they are setting a benchmark for how digital images are originated, published, consumed, and monetized online. This strategic move aligns with the critical need for enhanced security in the contextual advertising market, projected to reach over $500 billion by 2030, which sports enterprises can take advantage of to help ensure their continued profitability.
“SmartFrame and Truepic’s partnership represents a significant leap forward in digital media integrity,” said Jeffrey McGregor, CEO of Truepic. “SmartFrame’s cutting edge image-streaming network paired with Truepic’s authenticity infrastructure introduces the most efficient way for commercial partners to assure the integrity and ownership of media collections. We are proud to partner with a forward-thinking organization like SmartFrame on industry leading content integrity products.”
"As a fellow member of the C2PA, it's clear that the need for trust, security, and transparency in online visual content is as critical to SmartFrame as it is to Truepic,” explains Rob Sewell, CEO of SmartFrame Technologies. “This shared vision forms the cornerstone of our partnership. By integrating Truepic's widely respected authentication technology into our secure image publishing network, we gain the capability to authenticate images swiftly and effectively, and to provide users with a seamless and trustworthy experience. This collaboration marks the next phase in our mission to provide the highest level of protection and transparency for online content, and we are excited to embark on this journey with a company as esteemed as Truepic."
About Truepic
Truepic provides authenticity infrastructure for the internet. The company’s transparency tools deliver verifiable information about the origin and editing history of digital content. Truepic is dedicated to advancing products and services that establish transparency in digital content, empowering viewers and users to identify authenticity and differentiate human from computer-generated. Recognized as one of TIME’s Best Inventions and Fast Company’s World Changing Ideas, consumers, businesses, creators, and publishers trust Truepic’s technologies to make informed decisions. For more information, visit truepic.com.
About SmartFrame Technologies
Founded in 2015, SmartFrame Technologies is a London-based technology provider whose image streaming platform redefines the standard for online image publishing. It unites sports brands and other content owners with publishers, advertisers, and online audiences, and ensures that images are delivered in the highest quality with maximum security, clear provenance, and detailed analytics. Furthermore, through its contextual ad tech component, brands can reach audiences with high-impact, contextually targeted, in-image advertising and sponsorship placements in a way that recognizes the interests of its viewers and simultaneously complies with global privacy regulations.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240213285238/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release
News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release
Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
